taselisib (GDC-0032)

News alerts, weekly reports and conference planners

Company:

Roche

Drug class:

PI3Kα inhibitor

Related drugs:

PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	GDC-0032 Sensitive: B - Late Trials GDC-0032 Sensitive : B	GDC-0032 Sensitive: B - Late Trials GDC-0032 Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	GDC-0032 Sensitive: B - Late Trials GDC-0032 Sensitive : B	GDC-0032 Sensitive: B - Late Trials GDC-0032 Sensitive : B
FGFR1 mutation	Breast Cancer	FGFR1 mutation	Breast Cancer	GDC-0032 Resistant: B - Late Trials GDC-0032 Resistant : B	GDC-0032 Resistant: B - Late Trials GDC-0032 Resistant : B
TP53 mutation	Breast Cancer	TP53 mutation	Breast Cancer	GDC-0032 Resistant: B - Late Trials GDC-0032 Resistant : B	GDC-0032 Resistant: B - Late Trials GDC-0032 Resistant : B
PTEN mutation	Breast Cancer	PTEN mutation	Breast Cancer	GDC-0032 Resistant: B - Late Trials GDC-0032 Resistant : B	GDC-0032 Resistant: B - Late Trials GDC-0032 Resistant : B
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	GDC-0032 Sensitive: C2 – Inclusion Criteria GDC-0032 Sensitive : C2	GDC-0032 Sensitive: C2 – Inclusion Criteria GDC-0032 Sensitive : C2
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	palbociclib + GDC-0032 Sensitive: C3 – Early Trials palbociclib + GDC-0032 Sensitive : C3	palbociclib + GDC-0032 Sensitive: C3 – Early Trials palbociclib + GDC-0032 Sensitive : C3
PIK3CA mutation + ER negative	Breast Cancer	PIK3CA mutation + ER negative	Breast Cancer	palbociclib + GDC-0032 Sensitive: C3 – Early Trials palbociclib + GDC-0032 Sensitive : C3	palbociclib + GDC-0032 Sensitive: C3 – Early Trials palbociclib + GDC-0032 Sensitive : C3
CCNE1 overexpression + PIK3CA muattion + ER positive	HER2 Negative Breast Cancer	CCNE1 overexpression + PIK3CA muattion + ER positive	HER2 Negative Breast Cancer	palbociclib + GDC-0032 Sensitive: C3 – Early Trials palbociclib + GDC-0032 Sensitive : C3	palbociclib + GDC-0032 Sensitive: C3 – Early Trials palbociclib + GDC-0032 Sensitive : C3
PIK3CA mutation + ER negative	Solid Tumor	PIK3CA mutation + ER negative	Solid Tumor	palbociclib + GDC-0032 Sensitive: C3 – Early Trials palbociclib + GDC-0032 Sensitive : C3	palbociclib + GDC-0032 Sensitive: C3 – Early Trials palbociclib + GDC-0032 Sensitive : C3
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	tamoxifen + GDC-0032 Sensitive: C3 – Early Trials tamoxifen + GDC-0032 Sensitive : C3	tamoxifen + GDC-0032 Sensitive: C3 – Early Trials tamoxifen + GDC-0032 Sensitive : C3
PIK3CA mutation	Head and Neck Cancer	PIK3CA mutation	Head and Neck Cancer	GDC-0032 Sensitive: C3 – Early Trials GDC-0032 Sensitive : C3	GDC-0032 Sensitive: C3 – Early Trials GDC-0032 Sensitive : C3
PIK3CA mutation	Lung Non-Small Cell Squamous Cancer	PIK3CA mutation	Lung Non-Small Cell Squamous Cancer	GDC-0032 Sensitive: C3 – Early Trials GDC-0032 Sensitive : C3	GDC-0032 Sensitive: C3 – Early Trials GDC-0032 Sensitive : C3
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	alpelisib + GDC-0032 Sensitive: C3 – Early Trials alpelisib + GDC-0032 Sensitive : C3	alpelisib + GDC-0032 Sensitive: C3 – Early Trials alpelisib + GDC-0032 Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	GDC-0032 Sensitive: C3 – Early Trials GDC-0032 Sensitive : C3	GDC-0032 Sensitive: C3 – Early Trials GDC-0032 Sensitive : C3
CCNE2 overexpression + PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	CCNE2 overexpression + PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	GDC-0032 Sensitive: C3 – Early Trials GDC-0032 Sensitive : C3	GDC-0032 Sensitive: C3 – Early Trials GDC-0032 Sensitive : C3
PIK3CA amplification	Squamous Cell Carcinoma of Head and Neck	PIK3CA amplification	Squamous Cell Carcinoma of Head and Neck	GDC-0032 Sensitive: D – Preclinical GDC-0032 Sensitive : D	GDC-0032 Sensitive: D – Preclinical GDC-0032 Sensitive : D
PIK3CA E542K	Squamous Cell Carcinoma of Head and Neck	PIK3CA E542K	Squamous Cell Carcinoma of Head and Neck	GDC-0032 Sensitive: D – Preclinical GDC-0032 Sensitive : D	GDC-0032 Sensitive: D – Preclinical GDC-0032 Sensitive : D
PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck	PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck	GDC-0032 Sensitive: D – Preclinical GDC-0032 Sensitive : D	GDC-0032 Sensitive: D – Preclinical GDC-0032 Sensitive : D
PIK3CA H1047R	Squamous Cell Carcinoma of Head and Neck	PIK3CA H1047R	Squamous Cell Carcinoma of Head and Neck	GDC-0032 Sensitive: D – Preclinical GDC-0032 Sensitive : D	GDC-0032 Sensitive: D – Preclinical GDC-0032 Sensitive : D
PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck	PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck	GDC-0032 Sensitive: D – Preclinical GDC-0032 Sensitive : D	GDC-0032 Sensitive: D – Preclinical GDC-0032 Sensitive : D
PTEN mutation	Squamous Cell Carcinoma of Head and Neck	PTEN mutation	Squamous Cell Carcinoma of Head and Neck	GDC-0032 Resistant: D – Preclinical GDC-0032 Resistant : D	GDC-0032 Resistant: D – Preclinical GDC-0032 Resistant : D

taselisib (GDC-0032)

Associations
(22)

Associations
(22)

taselisib (GDC-0032)

Associations(22)

Associations(22)

Associations
(22)

Associations
(22)